日本生物技术论坛:伦敦2010。

Idrugs Pub Date : 2010-11-01

Asma Al-Shamahi

{"title":"日本生物技术论坛:伦敦2010。","authors":"Asma Al-Shamahi","doi":"","DOIUrl":null,"url":null,"abstract":"The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"756-8"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Japan Biotech Forum: London 2010.\",\"authors\":\"Asma Al-Shamahi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 11\",\"pages\":\"756-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在伦敦举行的日本生物技术论坛的主题包括日本制药和生物技术行业的新许可发展。本次会议报告重点介绍了几家日本公司关于许可机会的演讲，包括CanBas、LivTech、REGiMMUNE、D Western Therapeutics Institute和Chiome Bioscience。讨论的研究药物包括CBP-501 (CanBas)、LIV-2008 (LivTech)、RGI-2001 (REGiMMUNE)、IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku)和anti-Sema 3A (Chiome Bioscience)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Japan Biotech Forum: London 2010.

The Japan Biotech Forum, held in London, included topics covering new licensing developments in the Japanese pharma and biotech industries. This conference report highlights selected presentations on licensing opportunities from several Japanese companies, including CanBas, LivTech, REGiMMUNE, D Western Therapeutics Institute and Chiome Bioscience. Investigational drugs discussed include CBP-501 (CanBas), LIV-2008 (LivTech), RGI-2001 (REGiMMUNE), IVX-214 (D Western Therapeutics Institute/ Nippon Shinyaku) and anti-Sema 3A (Chiome Bioscience).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Idrugs 医学-药学

自引率

0.00%

发文量

审稿时长

>12 weeks